-+ 0.00%
-+ 0.00%
-+ 0.00%

Evercore ISI Group Maintains Outperform on Vertex Pharmaceuticals, Lowers Price Target to $475

Benzinga·09/11/2025 13:53:14
Listen to the news
Evercore ISI Group analyst Liisa Bayko maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Outperform and lowers the price target from $510 to $475.